Eric Lawitz

Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis

B. Neuschwander‐Tetri, N. Chalasani, P. Traber, 2016, Alimentary pharmacology & therapeutics.

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

Bachirou O Taddé, U. Akarca, C. Corpechot, 2023, The New England journal of medicine.